These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31122860)

  • 1. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.
    Choi WS; Choi JH; Jung DS; Choi HJ; Kim YS; Lee J; Jang HC; Shin EC; Park JS; Kim H; Cheong HJ
    Vaccine; 2019 Jun; 37(27):3605-3610. PubMed ID: 31122860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
    Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
    Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
    Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
    Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
    Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
    Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
    J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
    Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
    Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunogenicity and safety of zoster vaccine in Taiwanese adults.
    Yao CA; Chen LK; Huang KC
    Vaccine; 2015 Mar; 33(13):1515-7. PubMed ID: 25681662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.
    Choi WS; Choi JH; Choi JY; Eom JS; Kim SI; Pai H; Peck KR; Sohn JW; Cheong HJ
    J Korean Med Sci; 2016 Jan; 31(1):13-7. PubMed ID: 26770032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Eberhardson M; Hall S; Papp KA; Sterling TM; Stek JE; Pang L; Zhao Y; Parrino J; Popmihajlov Z
    Clin Infect Dis; 2017 Oct; 65(7):1174-1182. PubMed ID: 29126292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
    Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
    Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.
    Chun JY; Kim K; Lee MK; Kang CK; Koh Y; Shin DY; Hong J; Choe PG; Kim NJ; Yoon SS; Park WB; Kim I; Oh MD
    BMC Infect Dis; 2021 Jan; 21(1):117. PubMed ID: 33499826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
    Gilderman LI; Lawless JF; Nolen TM; Sterling T; Rutledge RZ; Fernsler DA; Azrolan N; Sutradhar SC; Wang WW; Chan IS; Schlienger K; Schödel F; Silber JL;
    Clin Vaccine Immunol; 2008 Feb; 15(2):314-9. PubMed ID: 18077611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
    Vesikari T; Hardt R; Rümke HC; Icardi G; Montero J; Thomas S; Sadorge C; Fiquet A
    Hum Vaccin Immunother; 2013 Apr; 9(4):858-64. PubMed ID: 23319176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.
    Miller G; Schaefer H; Yoder S; Miller R; Winokur P; Kotloff K; Klassen D; Wierzbicki M; Amegashie C; Edwards K
    Transpl Infect Dis; 2018 Jun; 20(3):e12874. PubMed ID: 29512282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
    MacIntyre CR; Egerton T; McCaughey M; Parrino J; Campbell BV; Su SC; Pagnoni MF; Stek JE; Xu J; Annunziato PW; Chan IS; Silber JL
    Hum Vaccin; 2010 Nov; 6(11):894-902. PubMed ID: 20980796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
    Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
    Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults.
    Mullane KM; Winston DJ; Wertheim MS; Betts RF; Poretz DM; Camacho LH; Pergam SA; Mullane MR; Stek JE; Sterling TM; Zhao Y; Manoff SB; Annunziato PW
    J Infect Dis; 2013 Nov; 208(9):1375-85. PubMed ID: 23908479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.